Test the Waters
TTC Oncology

TTC Oncology

Innovating Safer Solutions for the Treatment of Metastatic Breast Cancer

Founded in 2015 as an R&D, pre-revenue startup, TTC Oncology’s mission is to develop and bring to market a novel, small-molecule therapy to address unmet needs of breast cancer patients. TTC Oncology has a license from the University of Illinois at Chicago covering the therapy associated with modulation and mimicry of estrogen actions. TTC Oncology completed a Phase I trial of their proprietary drug at four clinical sites under the guidance of breast cancer oncologists and consultants with extensive experience in pharma and biotech.  TTC Oncology has $6.2 million invested toda...

View on Wefunder
Security Type
Min Investment
Minneapolis, MN
Offering Date
September 10, 2021
Expected Close Date
December 09, 2021


Arkadiusz Dudek
Chief Executive Officer
Fundraising that allowed completion of phase 1 clinical trial.

Arkadiusz Dudek, Chief Medical Officer
Completion of Phase 1 clinical trial with TTC352

Debra Tonetti, Chief Scientific Officer
Discovery of biomarker of resistance to hormonal therapy.

Research Reports

No reports have been submitted

Become a Reporter

Security Description

A SAFE is an agreement between you—the investor—and the company in which the company promises to give you a future equity stake based on the amount you invested. It also involves some kind of a triggering event that must take place in order for you to get your future equity stake. Be careful as you may only get equity if a particular event is triggered.

Key Deal Facts

Novel mechanism of action therapy for hormone resistant of breast cancer.
Intellectual property protected until 2033.
Safe and well tolerated oral capsule therapy.
Biomarker that identifies breast cancer that will respond well to TTC-352.
Completed first in human clinical trial.